Growth Metrics

Emergent BioSolutions (EBS) Accounts Payables (2016 - 2026)

Emergent BioSolutions has reported Accounts Payables over the past 17 years, most recently at $39.5 million for Q1 2026.

  • For Q1 2026, Accounts Payables fell 32.01% year-over-year to $39.5 million; the TTM value through Mar 2026 reached $39.5 million, down 32.01%, while the annual FY2025 figure was $55.6 million, 8.7% down from the prior year.
  • Accounts Payables for Q1 2026 was $39.5 million at Emergent BioSolutions, down from $55.6 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $124.2 million in Q1 2023 and troughed at $39.5 million in Q1 2026.
  • A 5-year average of $87.6 million and a median of $100.2 million in 2024 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: increased 15.75% in 2023 and later plummeted 45.72% in 2024.
  • Year by year, Accounts Payables stood at $103.5 million in 2022, then increased by 8.41% to $112.2 million in 2023, then crashed by 45.72% to $60.9 million in 2024, then decreased by 8.7% to $55.6 million in 2025, then decreased by 28.96% to $39.5 million in 2026.
  • Business Quant data shows Accounts Payables for EBS at $39.5 million in Q1 2026, $55.6 million in Q4 2025, and $57.4 million in Q3 2025.